J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Executive Summary
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.
You may also be interested in...
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.
Mohawk Tribe Questions Patent Board's Impartiality In Restasis Case
Supreme Court's concern about 'panel stacking' reflected in Mohawk Tribe's request to know the identity of PTAB members deciding its request to toss inter partes review.